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ABSTRACT
Zidovudine is a type of antiretroviral drug used for the treatment of human immunodeficiency virus (HIV) infection. 
This study investigated its effect on liver enzymes in adult male albino rats. Fifteen male albino rats weighing 
between 180-250g were used for the study. The rats were subdivided into a control (A) and two test groups (B and 
C) (n=5 each). For 25 days, the test groups (B and C) received a daily dosage of 6mg/kg and 12mg/kg of the drug 
solutions (in sterile water) via an oral cannula, while the control group (A) received normal feed and water only. The 
results showed that Zidovudine caused significant increase in the level of alanine transaminase (ALT) in the high-
dose treated rats, but no significant change in aspartate transaminase (AST) and alkaline phosphatase (ALP) in both 
the high and low-dose treated rats; and alanine transaminase (ALT) in the low-dose treated rats. Our findings 
suggest that high dose of Zidovudine can induce increase in the level of ALT in the treated animals. It also 
demonstrates that the use of antiretroviral drugs could have adverse effects on the liver that could lead to hepatic 
damage in normal subjects as the experimental rats used were HIV free.
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INTRODUCTION
With the increasing prevalence of HIV/AIDS, different antiretroviral drugs have been used to combat the 
progression of the disease. One of such drugs is Zidovudine which is a potent inhibitor of replication of HIV cells 
(Wright, 2004). It is phosphorylated in both infected and non-infected cells to monophosphate (MP) -a derivative of 
cellular thymidine kinase, and subsequently phosphorylated to diphosphate and then to a triphosphate (TP). This 
process is catalyzed by the enzyme cellular thymidine kinase and AZT-TP acts as an inhibitor substrate for the viral 
reverse transcriptase. Usually, the formation of further pro-viral DNA is blocked by the incorporation of MP into the 
chain and subsequently a chain termination competition by AZT-TP occurs. According to Wright (2008), HIV 
reverse transcriptase is approximately 100 fold greater compared to cellular DNA polymerase alpha.
On the other hand, the liver is one of the major organs involved in the metabolism of food and foreign substances 
including drugs. It performs more than 500 vital metabolic functions (Wilson, 2008). It is involved in the synthesis 
of products like glucose, plasma proteins, clotting factors and urea released into the blood stream. Hence the effect 
of zidovudine on liver functions is of paramount importance and should not be overlooked. Therefore, this study is 
intended to determine the effect of Zidovudine on liver function with the specific objectives of assessing the effect 
of zidovudine on body weight, Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT).
  ISSN: 2315 - 5388 E-ISSN: 2384 - 681X




Drug of Study: The antiretroviral drug considered in this study is a single-dose zidovudine tablet (300mg). It was 
obtained from the antiretroviral unit of the Central Hospital, Agbor, Delta State, Nigeria, but manufactured by 
Aurobindo Pharma Limited, Unit 3, Survey No. 313, Bachupally Village, Quthubullapur Mandal, Ranga Reddy 
District (A.P), India.
Animal care and handling: Fifteen (15) male albino Wistar rats weighing 180-250 grams were purchased from the 
animal house of Ambrose Alli University (AAU), Ekpoma, Edo State, Nigeria, and maintained under a controlled 
condition of temperature (33±2%), humidity and light (12 hours of light and dark) in the animal house of Delta State 
University, Abraka, Delta State, Nigeria. The animals were fed twice daily with standard pellet diet -grower mash 
and clean tap water. The animals were housed in a standard environmental condition in wire-mesh-bottomed 
wooden cage and allowed to acclimatize for seven (7) days before drug administration.
Experimental design: Fifteen (15) male Albino wistar rats weighing between 180-250grams were randomly 
assigned into three (3) groups (A, B and C) (n=5 each). Groups B and C served as test groups while A served as 
control. Relying on the therapeutic dose of zidovudine in humans (300mg), the corresponding therapeutic dose for 
rat models was calculated and aqueous formulated solution was administered as follows: rats in group B and C
received 6mg/kg (low dose) and 12mg/kg (high dose) per day respectively for 25 days, while the rats in group A
received normal feed and water only. All administrations were performed via oral intubations.
Blood sample collection and analysis: Having anaesthesized the rats in a chloroform saturated chamber, blood 
samples were collected by cardiac puncture using 5m1 hypodermal syringe and needle, and placed in an 
anticoagulant bottle. The serum was used for the assay of the hepatic enzymes activities (AST, ALT and ALP), 
using the Humazym Muv-test kits.
Estimation of the transaminase: Aspartate transaminase (AST) and Alanine transaminase (ALT) activities were 
assayed by the Reitman and Frankel method (Ashwood and Border, 1996) using Beckman spectro photometer.
Alkaline phosphate estimation: The method of King and Armstrong (Reiching and Kaplan, 1988) was employed 
for the estimation of alkaline phosphatase (ALP).
Statistics analysis: Data was analyzed separately using paired t-test and results were expressed as mean ± standard 
deviation to determine significant differences between means. P< 0.05 was regarded a significant.
RESULTS
After careful application of all the procedures outlined above, the results obtained showed that Zidovudine caused 
significant increase in the level of alanine transaminase (ALT) in the high-dose treated rats, but no significant 
change in aspartate transaminase (AST) and alkaline phosphatase (ALP) in both the high and low-dose treated rats, 
and alanine transaminase (ALT) in the low-dose treated rats (see tables 1, 2, 3, 4 and 5). 

















Values were express in mean ± standard error of mean (S.E.M) (n=5). There was no significant increase in body
weight (P>0.05).
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Table 2: Showing the comparison of body weight of control and low dose treated rats.




3.4 ± 1.52 1.2 ± 0.08 3.23 2.31 P<O.05 Significant
Result presented in mean ± SD (n=5). There was a significant increase in the body weight of the zidovudine low 
dose treated wistar rats when compared with the control (P>0.05).
Table 3: Showing the comparison of body weight of control to high dose treated rats
GROUP CONTROL HIGH
DOSE




3.4 ± 1.52 0.0± 0.1 5.0 2.31 P<0.05 Significant
Result presented in mean ± SD (n = 5).There was a significant increase in the body weight of the wistar rat treated 
with zidovudine in high dose (12mg/kg) for 25 days when compared to the control.
Table 4: Showing the effect of zidovudine on the liver function in low dose (6mg/kg) treated rats






















Result presented in mean ± SD (n = 5).There was no significant change in the level of AST, ALT and ALP of the 
wistar treated for 25 days with zidovudine in low dose when compared with the control. Key: AST: Aspartate 
Transaminase; ALT: Alanine Aminotransferase; ALP: Alkaline Phosphate
Table 5: Showing the effect of zidovudine on the liver function in high dose (12mg/kg) treated rats






















Result presented in mean ± SD (n = 5).There was no significant change in the level of AST and ALP of the wistar 
rat treated for 25 days with zidovudine in high dose when compared with the control but there was a significant 
increase in ALT (P<O.05) when compared with the control. Key: AST: Aspartate Aminotransferase; ALT: Alanine 
Transaminase; ALP: Alkaline Phosphate
DISCUSSION
Hepatic toxicity appears to be a more frequent consequence of long term (3-12 months) exposure to zidovudine and 
increases in liver enzyme activity have been accompanied by hepatomegaly with macro vesicular steatosis and 
frequently, fatal lactic acidosis (Freiman et al., 1993; Chariot et al., 1991). In this study, the effects of zidovudine 
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(an antiretroviral drug) on some liver enzymes were examined. We demonstrated a statistically significant increase 
in the level of ALT after treatment with zidovudine in high dose for 25 days. 
However, there was no significant change on the weight, AST and ALP, after the course of treatment in both high 
and low dose of zidovudine. There are several possible explanations for the observed increase in the level of ALT; 
though the exact mechanism by which zidovudine cause adverse hepatic effect has not been elucidated. William 
(1995) had reported that zidovudine induces liver injury occurs via at least six mechanisms involving various 
intracellular organelles, with consequent disruption of intracellular calcium homeostasis, decline in ATP levels and 
finally, hepatocyte swelling and rupture (Beanuc, 1987; Yun et al., 1993).
As indicated by the results of this study, only ALT was observed to have increased significantly at high dose of 
zidovudine administration for 25 days and available scientific evidence show that an elevation of this enzyme 
suggests hepatic damage, which often results from several mechanisms including the generation of free oxygen 
radicals and peroxidation of membranes e.t.c. (Urnar et al., 2008). It could be concluded therefore, that HIV patients 
on regular use of HAART containing zidovudine, may be at risk of liver damage.
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